Angelini Pharma Hellas

What Angelini Pharma Hellas does

Angelini Pharma Hellas Monoprosopi A.B.E.E. is a privately held Greek pharmaceutical subsidiary of Angelini Pharma S.p.A., itself part of the Italian privately held conglomerate Angelini Industries (founded 1919 in Ancona by Francesco Angelini, now led by the fourth-generation Angelini family). The Greek entity operates from Kifisia (Athens) and markets a portfolio focused on brain health and CNS (including epilepsy and mental health), pain, infectious diseases, consumer healthcare, gastroenterology, fertility, gynecology, cardiology, musculoskeletal, and immunology-dermatology. Its commercialized brands include Ontozry (cenobamate, an anti-epileptic with a dual mechanism of action combining GABAA allosteric modulation with persistent sodium current blockade), Latuda (lurasidone, atypical antipsychotic launched in Greece in January 2022), Trittico (trazodone), Vellofent (sublingual fentanyl for breakthrough cancer pain), Xydalba (dalbavancin IV antibiotic), Prixina (prulifloxacin), Importal (lactitol laxative), Verboril (diacerein for osteoarthritis), Dicloplast (diclofenac patch) and Tantum Verde (benzydamine oropharyngeal line), among others.

The underlying asset base is built on patented molecules, regulatory approvals across the European Commission, EMA and Greek national authorities, and a brand equity stack anchored by Tantum Verde's globally trusted oropharyngeal franchise and cenobamate's proprietary dual-mechanism IP. Revenue mechanics follow a traditional pharma model: prescription products (Rx) are reimbursed through Greek public and private payors via physician prescription, while OTC products (ΜΗ.ΣΥ.ΦΑ.) such as Tantum Verde, Dicloplast and Importal are sold directly through the Greek retail pharmacy network at prices set within the regulated Greek pharmaceutical pricing framework. Pricing is not publicly disclosed. Go-to-market is sales-led, with dedicated HCP engagement (Angelini HCP Portal, Harmonia Mentis digital hub), active participation in major European neurology and epilepsy congresses (EAN, IEC), disease awareness campaigns (e.g., Purple Day, schizophrenia awareness), and CSR/philanthropy programs supporting patient advocacy groups. Within the broader Angelini Pharma group operating in 20 direct countries with 3,000+ employees and products marketed in 70+ countries, Angelini Pharma Hellas functions as the Greek sales-and-distribution arm, with major upstream strategic moves (the Arvelle Therapeutics acquisition in February 2021 for up to $960 million to secure European cenobamate rights, and the Catalyst Pharmaceuticals acquisition announced in May 2026 for $4.1 billion to enter the US market) executed at the parent level.

The company's strategic positioning centers on three reinforcing pillars: (1) CNS franchise depth, anchored by cenobamate and supported by Trittico, Latuda, and the HEADWAY brain-health policy initiative co-developed with The European House – Ambrosetti; (2) consumer healthcare/OTC cash generation via Tantum Verde, Dicloplast and related brands; and (3) rare-disease expansion via licensed/optioned assets (CV-01 from Cureverse for Alzheimer's, radiprodil from GRIN Therapeutics) and the pending Catalyst portfolio (Amifampridine, Vamorolone, Perampanel). Capital backing by Angelini Industries (parent revenue exceeding €2 billion across healthcare, industrial technology and consumer goods; ~5,800 group employees in 21 countries) underwrites deal capacity, while institutional financing partners such as Blackstone and BNP Paribas appear in specific transactions.

Name

Angelini Pharma Hellas

Legal name

Angelini Pharma Hellas Monoprosopi A.B.E.E.

Website

https://angelinipharma.gr

Company type

Private

Founded year

1919

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Angelini Pharma Hellas is the Greek subsidiary of Italy's Angelini Pharma, commercializing prescription and OTC pharmaceuticals across brain health, mental health, epilepsy, pain, infectious diseases and consumer healthcare through the Greek retail pharmacy network and HCP engagement programs.

Ownership category

akta.pro rank

Headquarters

HQ city

Athens

HQ country

Greece

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Technology or R&D, Supply Chain, Operations, Infrastructure

Revenue model

1. Prescription Pharmaceutical Products: Revenue from prescription drugs across therapeutic areas including brain health (epilepsy, mental health), pain, consumer healthcare, and antimicrobials sold through pharmacies and hospitals in Greece.
2. Consumer Healthcare / OTC Products: Revenue from over-the-counter (OTC/ΜΗ.ΣΥ.ΦΑ.) products including Tantum Verde, Dicloplast, and other consumer health brands sold through pharmacies without prescription.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Angelini Pharma Hellas is the Greek commercial affiliate of Angelini Pharma, marketing a portfolio of branded prescription and OTC (ΜΗ.ΣΥ.ΦΑ.) pharmaceutical products in Greece across Central Nervous System (epilepsy, schizophrenia, depression, pain), infectious diseases, consumer healthcare (oropharyngeal inflammation, musculoskeletal pain, constipation), gastroenterology, fertility, gynecology, cardiology and rare diseases. The portfolio includes Ontozry (cenobamate), Latuda (lurasidone), Trittico (trazodone), Vellofent (fentanyl), Xydalba (dalbavancin), Prixina (prulifloxacin), Tantum Verde (benzydamine), Dicloplast (diclofenac patch) and Importal (lactitol), among others. Products are sold primarily through licensed retail pharmacies, with prescription lines requiring physician authorization and consumer-healthcare (OTC) lines dispensed without prescription.

Product overview

Angelini Pharma Hellas operates as the Greek subsidiary of Angelini Pharma, part of Angelini Industries. The company offers a diversified pharmaceutical portfolio focused on Brain Health (including Mental Health and Epilepsy), Pain management, Infectious Diseases, Consumer Healthcare, and Gastroenterology. Key products include Ontozry (cenobamate) for drug-resistant epilepsy, Latuda (lurasidone) for schizophrenia, Trittico (trazodone) for mental health, Vellofent (fentanyl) for pain, and the consumer healthcare line including Tantum Verde (benzydamine) for oropharyngeal inflammation and Dicloplast (diclofenac patch) for musculoskeletal pain. The company also markets Xydalba (dalbavancin) as an antibiotic, Importal (lactitol) for constipation, and Prixina (prulifloxacin) as an antimicrobial. Angelini Pharma operates in 20 countries directly with over 3,000 employees, marketing products in over 70 countries through strategic alliances.

Differentiator

Problem solved

Functional benefit

Products and services

• Ontozry (Cenobamate) Anti-epileptic prescription pharmaceutical containing cenobamate (available as 12.5mg+25mg starter, and 50mg/100mg/150mg/200mg tablets) for adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients inadequately controlled despite prior therapy. Sold through pharmacies in Greece with physician prescription, targeting the treatment-resistant epilepsy population.
• Latuda (Lurasidone) Atypical antipsychotic prescription pharmaceutical containing lurasidone (37mg or 74mg film-coated tablets) for the treatment of schizophrenia in adults and adolescents aged 13 years and older. Sold through Greek retail pharmacies with physician prescription.
• Trittico (Trazodone) Antidepressant prescription pharmaceutical containing trazodone (150mg or 300mg film-coated tablets) for the treatment of depression and related mental health conditions. Sold through Greek pharmacies with physician prescription.
• Vellofent (Sublingual Fentanyl) Prescription opioid analgesic containing sublingual fentanyl tablets in multiple strengths (67mcg, 133mcg, 267mcg, 400mcg, 533mcg and 800mcg per tablet) for the management of breakthrough cancer pain in opioid-tolerant patients. Sold through Greek pharmacies with restricted physician prescription.
• Xydalba (Dalbavancin) Intravenous antibiotic prescription pharmaceutical containing dalbavancin (500mg/vial as powder for concentrate for solution for infusion), a lipoglycopeptide indicated for the treatment of skin and soft tissue infections. Sold through hospital and specialty pharmacies in Greece with physician prescription.
• Prixina (Prulifloxacin) Antimicrobial prescription pharmaceutical containing prulifloxacin (600mg film-coated tablets), a fluoroquinolone antibacterial indicated for the treatment of infectious diseases. Sold through Greek pharmacies with physician prescription.
• Verboril (Diacerein) Prescription pharmaceutical containing diacerein (50mg hard capsules), an anti-inflammatory used in the treatment of osteoarthritis and related musculoskeletal conditions. Sold through Greek pharmacies with physician prescription.
• Tantum Verde (Benzydamine) OTC/ΜΗ.ΣΥ.ΦΑ. consumer healthcare product containing benzydamine with triple-action anti-inflammatory, analgesic and antiseptic properties for the symptomatic treatment of oropharyngeal inflammation. Available in pastilles (3mg), mouthwash (1.5mg/ml), toothpaste (5mg/g) and oral spray (3mg/ml in 15ml and 240ml formats). Sold without prescription through Greek retail pharmacies.
• Dicloplast (Diclofenac Patch) OTC/ΜΗ.ΣΥ.ΦΑ. consumer healthcare product in medicated plaster form containing diclofenac epolamine (180mg per patch), providing localized anti-inflammatory treatment and pain relief for up to 12 hours across musculoskeletal conditions including sports injuries, tendinitis, bursitis, chronic rheumatic disease, lower back pain, cervical syndrome and osteoarthritis. Sold without prescription through Greek retail pharmacies.
• Importal (Lactitol) OTC consumer healthcare product containing lactitol, an osmotic laxative marketed for symptomatic treatment of constipation. Available as oral solution and powder sachets, suitable for adults and children from 1 year of age. Sold without prescription through Greek retail pharmacies.

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Catalyst PharmaceuticalscoreStrategic or Co-development Partner · 8 May 2026Angelini Pharma announced acquisition of Catalyst Pharmaceuticals for 4.1 billion USD (3.5 billion euros). The acquisition marks Angelini's entry into the US market and strengthens its position in brain health and rare diseases. Catalyst brings a portfolio including Amifampridine (FDA-approved for Lambert-Eaton myasthenic syndrome), Vamorolone (FDA-approved for Duchenne muscular dystrophy), and Perampanel (antiepileptic). Completion expected Q3 2026.
• Quiver BiosciencecoreStrategic or Co-development Partner · 13 March 2026Angelini Pharma and Quiver Bioscience entered a strategic research collaboration and licensing agreement for the discovery and advancement of innovative therapies for genetic epilepsies. The collaboration combines Quiver's AI-powered drug discovery platform (GPS system) with Angelini's brain health expertise. Quiver receives an undisclosed upfront payment plus milestone payments up to 120 million USD, and royalties on sales. Angelini gains exclusive global licensing rights to identified pharmaceutical targets.
• SovargenminorStrategic or Co-development Partner · 22 September 2025Angelini Pharma signed an exclusive option agreement for global development and commercialization rights to an innovative brain health therapeutic candidate.
• GRIN TherapeuticscoreStrategic or Co-development Partner · 2 September 2025Angelini Pharma and GRIN Therapeutics (Blackstone Life Sciences) entered an exclusive collaboration for the development and commercialization of radiprodil outside North America. Radiprodil is a neuroprotective agent being developed for rare neurological conditions.
• TEHA GroupminorStrategic or Co-development Partner · 2 July 2025Angelini Pharma activated the HEADWAY epilepsy initiative in collaboration with the TEHA Group, presenting updated findings at the European Parliament in Brussels on July 2, 2025.
• Cureverse Inc.coreStrategic or Co-development Partner · 23 October 2024Angelini Pharma signed an exclusive option agreement for global development and commercialization rights to CV-01, a novel Nrf2 activator molecule in clinical Phase 1 for Alzheimer's disease with potential applications in brain health including epilepsy. Cureverse retains rights in South Korea, China, Hong Kong, Macau, and Taiwan. Deal includes upfront payment and milestone payments up to 360 million USD plus royalties.
• Lumira VenturesminorStrategic or Co-development Partner · 28 July 2021Angelini Pharma and Lumira Ventures launched the Angelini Lumira Biosciences Foundation (ALBF), a collaborative initiative for neuroscience research and development funding.
• Arvelle TherapeuticscoreStrategic or Co-development Partner · 2 February 2021Angelini Pharma completed the acquisition of Arvelle Therapeutics (Swiss-based CNS company) for up to 960 million USD. The deal gave Angelini exclusive European licensing rights to Cenobamate. Arvelle had received 207.8 million USD in seed funding from investors including NovaQuest, BRV Capital, LSP, H.I.G. BioHealth, Andera Partners, F-Prime Capital, and KB Investments.
• SK BiopharmaceuticalscoreTechnology or Integration · 1 January 2019SK Biopharmaceuticals licensed Cenobamate rights to Arvelle Therapeutics for Europe (subsequently acquired by Angelini Pharma). Angelini Pharma holds exclusive rights in the EU, Switzerland, and UK. Cenobamate is approved in the US (where SK commercializes it) and in Europe.
• The European House – AmbrosetticoreStrategic or Co-development Partner · 1 January 2017The European House – Ambrosetti (think tank) co-designed and launched the HEADWAY initiative with Angelini Pharma, creating a multidisciplinary platform for strategic reflection, analysis, and dialogue on brain health policy across Europe. Collaboration ongoing since 2017.
• Gamian Europe, EUFAMI, ILAE, IBE, Epilepsy Alliance EuropeminorStrategic or Co-development PartnerPatient organizations collaborating with the HEADWAY initiative. The initiative operates in alignment with WHO programs, activities, and strategies, and with scientific societies/patient associations (Gamian Europe, EUFAMI, ILAE, IBE, Epilepsy Alliance Europe) and European institutions.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Regional players

• Vianex: One of the largest Greek pharmaceutical companies, manufacturing and distributing branded generics and OTC products domestically. Direct local-market competitor to Angelini Pharma Hellas in Greece.
• ELPEN Pharmaceutical: Greek pharmaceutical company with branded generics and OTC products across respiratory, cardiovascular, and CNS. Comparable as a Greece-based pharma distributor and manufacturer.

Direct peers

• Menarini Group: Privately held Italian pharmaceutical group operating across branded pharma, consumer health, and diagnostics. Comparable as a family-owned Italian pharma peer with broad European distribution.
• Catalyst Pharmaceuticals: US specialty pharma focused on rare neurological diseases (Lambert-Eaton myasthenic syndrome, Duchenne muscular dystrophy). Currently being acquired by Angelini Pharma for $4.1B; a direct rare-neuro peer and future portfolio component.
• UCB: Belgian biopharmaceutical company with a leading epilepsy franchise (Vimpat, Keppra, Briviact) and CNS focus. Directly competes with Angelini's cenobamate/Ontozry in the treatment-resistant epilepsy space.
• Chiesi Farmaceutici: Privately held Italian pharma focused on respiratory, neonatology, and specialty care with strong European and emerging-market presence. Similar mid-size European pharma profile and family-owned governance.
• Lundbeck: Danish specialty pharmaceutical company focused on brain diseases (epilepsy, depression, schizophrenia). Highly comparable given similar CNS franchise concentration, branded-innovator model, and European commercial footprint.
• Recordati: Italian specialty pharma with branded products across CNS, rare diseases, and consumer health. Closest Italian-headquartered peer, with similar therapeutic-area diversification and European commercial model.

Emerging players

• SK Biopharmaceuticals: South Korean biotech that developed cenobamate and licenses it to Angelini Pharma for Europe. Comparable as the originator partner with shared exposure to the same molecule.

Broad incumbents

• Teva Pharmaceutical Industries: Global generics and specialty pharma leader with CNS assets (including Austedo for movement disorders). Comparable as a broad incumbent overlapping with Angelini in branded specialty and CNS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCVeo0ODHMm8Ev10jCLO4yag/featured
• LinkedInlinkedin.com/company/angelini-pharma-hellas-s-a-/mycompany/?viewAsMember=true

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Angelini Pharma Hellas